Incretin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-12. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Algolian Babon (アルゴル星人バボン, Arugoru Seijin Babon): Builjeek's partner and an underling of Agent X's from Planet Algol who is equipped with shoulder-mounted missile pods, an arm-mounted blaster, and a magic circle that allows him to absorb the Dekarangers' energy attacks who appears exclusively in the crossover film Mahō Sentai Magiranger vs. Dekaranger. He assists Agent X in obtaining the Flower of Heaven, but both are eventually deleted by the Magirangers and Dekarangers via the Flower of Heaven's power. Babon is voiced by Takashi Nagasako (長嶝 高士, Nagasako Takashi).
=== As a reducing agent === Sulfur dioxide is also a good reductant. In the presence of water, sulfur dioxide is able to decolorize substances. Specifically, it is a useful reducing bleach for papers and delicate materials such as clothes. This bleaching effect normally does not last very long. Oxygen in the atmosphere reoxidizes the reduced dyes, restoring the color. In municipal wastewater treatment, sulfur dioxide is used to treat chlorinated wastewater prior to release. Sulfur dioxide reduces free and combined chlorine to chloride. Sulfur dioxide is fairly soluble in water, and by both IR and Raman spectroscopy; the hypothetical sulfurous acid, H2SO3, is not present to any extent. However, such solutions do show spectra of the hydrogen sulfite ion, HSO3−, by reaction with water, and it is in fact the actual reducing agent present:
However, newer studies have shown that early wound closure and early fixation reduces infection rates, promotes fracture healing and early restoration of function. Therefore, assessment of all open fractures should include the mechanism of injury, the appearance of soft tissues, the likely levels of bacterial contamination and the specific characteristics of the fractures. Accurate assessment of the fracture can only be performed inside an operating theatre. For more comprehensive prognosis purposes other classification systems, such as the Sickness Impact Profile (as a health status measure), Mangled Extremity Severity Score (MESS) and Limb Salvage Index (LSI) (decision to amputate or salvage a limb), have been devised by Dr Shanmuganathan Rajasekaran.
=== Effectiveness === Even though it is not a cure for kidney failure, dialysis is a very effective treatment. Survival rates of kidney failure are generally longer with dialysis than without (having only conservative kidney management). However, from the age of 80 and in elderly patients with comorbidities there is no difference in survival between the two groups.
Sources: en.wikipedia.org
=== Size and length === There is no identified correlation between the size of the glans or clitoris as a whole, and a woman's age, height, weight, use of hormonal contraception, or being postmenopausal, although women who have given birth may have significantly larger clitoral measurements. Centimetre and millimetre measurements of the clitoris show variations in size. The clitoral glans has been cited as typically varying from 2 mm to 1 cm (less than an inch) and usually being estimated at 4 to 5 mm in both the transverse and longitudinal planes. A 1992 study concluded that the total clitoral length, including glans and body, is 16.0 ± 4.3 mm (0.63 ± 0.17 in), where 16 mm (0.63 in) is the mean and 4.3 mm (0.17 in) is the standard deviation. Concerning other studies, researchers from the Elizabeth Garrett Anderson and Obstetric Hospital in London measured the labia and other genital structures of 50 women from the age of 18 to 50, with a mean age of 35.6., from 2003 to 2004, and the results given for the clitoral glans were 3–10 mm for the range and 5.5 [1.7] mm for the mean. Other research indicates that the clitoral body can measure 5–7 centimetres (2.0–2.8 in) in length, while the clitoral body and crura together can be 10 centimetres (3.9 in) or more in length.
Following Donald Trump's victory in the 2024 U.S. presidential election, several prominent tech industry figures expressed support for positions aligned with effective accelerationism, particularly regarding deregulation and technological advancement. The potential appointment of Elon Musk to government roles focused on auditing federal programs drew support from venture capitalists who anticipated reduced regulatory oversight of the technology sector. Notable tech figures publicly connected these developments to the movement's principles. Aaron Levie, CEO of Box, expressed support for "removing unnecessary red tape and over-regulation", while Mark Pincus, early Facebook investor and Zynga founder, explicitly referenced "effective accelerationism" in his post-election commentary. Venture capitalists viewed the incoming administration as an opportunity to ease regulations that had affected technology mergers and acquisitions during the previous years.
The original Pennsylvania Station was an ornate station building designed by McKim, Mead, and White and considered a masterpiece of the Beaux-Arts style. Completed in 1910, it enabled direct rail access to New York City from the south for the first time. Its head house and train shed were torn down in 1963 at a time of low train ridership, with the rail infrastructure reconstituted as the smaller underground station that survives today. The New York Times editorial board described the demolition of the original station as a "monumental act of vandalism", and its destruction galvanized the modern historic preservation movement. As rail travel increased again in the following decades, the underground station began to operate beyond its design capacity. By 2015, the station handled 650,000 travelers daily (more than the region's three major airports combined) and had become loathed for its cramped, claustrophobic conditions. The 2020s saw the opening of Moynihan Train Hall, a head house that expanded Penn Station into the Farley building, as well as expansion of the LIRR concourse and a new direct entrance from 33rd Street. Plans under development call for reconstruction of the core of the station, with competing proposals regarding the station's relationship to Madison Square Garden under consideration. Looking back on the pace of reconstruction since the announcement of Moynihan Hall in 1999, the Times noted in 2025 that "More than 25 years, five presidencies and four governors later, the plan to rebuild Penn Station is nowhere near completion."
== Career == Townsend held various academic positions at the Medical University of South Carolina, starting as a Research Assistant Professor (2004) in the Department of Pharmaceutical Sciences. She was appointed as an associate professor in the Drug Discovery and Biomedical Sciences department in 2015 and has been serving as a Professor and acting department chair. In 2021, Townsend became the co-director of the Administrative Core for the Redox COBRE.
== Function in protein termination == Protein elongation continues until a stop codon appears on the mRNA. A Class I release factor (RF1 or RF2) binds to the stop codon, which induces hydrolysis of the tRNA-peptide bond in the P site, allowing the newly-formed protein to exit the ribosome. The nascent peptide continues to fold and leaves the 70S ribosome, the mRNA, the deacylated tRNA (P site), and the Class I release factor (A site). In a GTP-dependent manner, the subsequent recycling is catalyzed by a Class II release factor named RF3/prfC, Ribosome recycling factor (RRF), Initiation Factor 3 (IF3) and EF-G. The protein RF3 releases the Class I release factor so that it may occupy the ribosomal A site. EF-G hydrolyzes GTP and undergoes a large conformational change to push RF3 down the ribosome, which occurs alongside tRNA dissociation and promotes the ribosomal subunit rotation. This motion actively splits the B2a/B2b bridge, which connects the 30S and the 50S subunits, so that the ribosome can split. IF3 then isolates the 30S subunit to prevent re-association of the large and small subunits.
Sources: en.wikipedia.org
== Interactions == Patiromer was tested for drug-drug interactions with 28 drugs and showed binding or interaction with 14 of these drugs. This could reduce their availability and thus effectiveness, wherefore patiromer has received a boxed warning by the US Food and Drug Administration (FDA), telling patients to wait for at least six hours between taking patiromer and any other oral drugs. Of the 14 drugs that did show an interaction in vitro, 12 were selected for further testing in phase 1 studies in healthy volunteers to assess whether the results seen in vitro translated into an effect in people. These studies showed patiromer did not alter the absorption of nine of the 12 drugs when co-administered. Patiromer reduced absorption of three drugs when co-administered, however, there was no interaction when patiromer and these three drugs were taken 3 hours apart. This information was submitted to the FDA in the form of a supplemental New Drug Application (sNDA) and as a result, in November 2016 the FDA approved the removal of the boxed warning regarding the separation of patiromer and other oral medications. The updated label recommends patients take patiromer at least three hours before or three hours after other oral medications.
It was not until he [Trask] had exercised for some time that he could perform any labor ... [H]is neck and back have continued to curve drawing his head downward on his breast. The account of Trask became the first documented case of AS in the United States, owing to its indisputable description of inflammatory disease characteristics of AS and the hallmark of deforming injury in AS. In the late nineteenth century, the neurophysiologist Vladimir Bekhterev of Russia in 1893, Adolf Strümpell of Germany in 1897, and Pierre Marie of France in 1898 were the first to give adequate descriptions which permitted an accurate diagnosis of AS prior to severe spinal deformity. For this reason, AS is also known as Bekhterev disease, Bechterew's disease or Marie–Strümpell disease. The word is from Greek ankylos meaning crooked, curved or rounded, spondylos meaning vertebra, and -itis meaning inflammation.
== Mass spectrometry == Mass spectrometry has been successfully used to identify changes in the composition of the adhesome upon perturbation. Schiller et al. as well as Kuo et al. examined the effect of inhibition of myosin contractility on the integrin adhesome composition and found LIM domain proteins and beta-PIX to be tension sensitive. Gou et al. found little change in the cadherin adhesome after calcium depletion from the media, which essentially abrogates cell-cell adhesion. Reinhard Fassler and co-workers used proteomics on specifically engineered cell lines to distinguish between the adhesome of β1- and αv-class integrins.
Half-Life 2: Episode Two is a 2007 first-person shooter game developed and published by Valve. Following Episode One (2006), it is the second of two episodic games that continue the story of Half-Life 2 (2004). The player controls Gordon Freeman, who travels through the mountains surrounding City 17 to a resistance base with his ally Alyx Vance. Like previous Half-Life games, Episode Two combines shooting, puzzle-solving and narrative elements, and adds expansive environments and less linear sequences. Episode Two was released on October 10, 2007, for Windows on Valve's distribution service Steam, and as a part of The Orange Box, a compilation of Valve games for Windows, Xbox 360, and PlayStation 3. The PlayStation version was produced by Electronic Arts. Episode Two received positive reviews. Valve canceled Half-Life 2: Episode Three when they abandoned episodic development and began developing a new game engine. In 2020, after canceling several further Half-Life projects, Valve released Half-Life: Alyx.
==== Marine algae ==== The factors affecting δD of algal lipids are: δD of water, algal species (up to 160%), lipid type (up to 170%), salinity (+0.9±0.2% per PSU), growth rate (0 ~ −30% per day) and temperature (−2 ~ −8% per °C). In a study by Zhang et al. (2009), the δDs of fatty acids in Thalassiosira pseudonana chemostat cultures were −197.3‰, −211.2‰ and −208.0‰ for C14, C16 and C18 fatty acids respectively. The δD of C16 fatty acid in the algae A. e. unicocca at 25°C, was determined using the empirical equation y = 0.890x − 91.730, where x is the δD of water at harvest. For another algal species, B. v. aureus, the equation was y = 0.869x − 74.651. The degree of D/H fractionation in most algal lipids increases with increasing temperature and decreases with increasing salinity. The growth rates have different impacts on the D/H fractionation depending on the species types.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.